JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 47(2013) N 4 p. 538-543;
Y.H. Noh1, J.Y. Kim1, D.H. Kim1,2, O.H. Kim1, J.H. Park1,2, B.S. Kee3, D.S. Sohn4, Y.H. Chung1, K.Y. Kim1, W.B. Lee1*, S.S. Kim1**

Recovery from Parkinsonism with N-acetylcysteine-differentiated neurons

1Department of Anatomy and Cell Biology, College of Medicine, Chung-Ang University, Seoul, 156756, Korea
2BioGrand Biomedical Research Center, BioGrand Inc., Gyeonggi, 427800, Korea
3Department of Psychiatry, College of Medicine, Chung-Ang University, Seoul, 156756, Korea
4Department of Thoracic Surgery, College of Medicine, Chung-Ang University, Seoul, Korea

*whitefox@cau.ac.kr
**sungsu@cau.ac.kr
Received - 2012-09-11; Accepted - 2012-09-21

The upregulation of dopaminergic neuronal differentiation is necessary for stem cell therapy in Parkinson's disease (PD). In this study, neuronal differentiation efficiency increased by more than 2 times in P19 embryonic stem cells (ESCs) induced by N-acetylcysteine (NAC) and retinoic acid (RA) as compared to RA alone, with suppressed glial differentiation. The majority of NAC-treated stem cells grafted into brains of PD mice differentiated into dopaminergic neurons and persisted well for 6 weeks. Parkinsonism was also greatly improved after grafting NAC-treated cells in comparison to cells treated with only RA. Our results strongly suggest that NAC treatment may be an effective strategy for generating stem cells fated to become dopaminergic neurons for PD clinical therapy.

P19 embryonic stem cell, N-acetylcysteine, differentiation, dopaminergic neuron, Parkinson's disease



JMB-FOOTER RAS-JOURNALS